Compounds > losartan

losartan and desipramine

losartan has been researched along with desipramine in 12 studies

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (8.33)	18.2507
2000's	5 (41.67)	29.6817
2010's	6 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Strassburg, CP; Tukey, RH	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Avdeef, A; Tam, KY	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Gard, PR; Mandy, A; Sutcliffe, MA	1
Dendorfer, A; Dominiak, P; Raasch, W; Ziegler, A	1
Georgiev, V; Tchekalarova, J	1

Reviews

2 review(s) available for losartan and desipramine

Article	Year
Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annual review of pharmacology and toxicology, 2000, Volume: 40 Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic	2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

10 other study(ies) available for losartan and desipramine

Article	Year
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? Journal of medicinal chemistry, 2010, May-13, Volume: 53, Issue:9 Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
Evidence of a possible role of altered angiotensin function in the treatment, but not etiology, of depression. Biological psychiatry, 1999, Apr-15, Volume: 45, Issue:8 Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Binding Sites; Cell Culture Techniques; Depression, Postpartum; Desipramine; Disease Models, Animal; Female; Fluoxetine; Humans; Losartan; Male; Mice; Receptors, Angiotensin; Tranylcypromine	1999
Reduction of vascular noradrenaline sensitivity by AT1 antagonists depends on functional sympathetic innervation. Hypertension (Dallas, Tex. : 1979), 2004, Volume: 44, Issue:3 Topics: Adrenergic alpha-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Atropine; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Desipramine; Diastole; Dose-Response Relationship, Drug; Losartan; Male; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Propranolol; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-2; Reserpine; Sympathectomy, Chemical; Sympathetic Nervous System; Symporters; Tetrazoles; Tubocurarine; Yohimbine	2004
Ang II and Ang III modulate PTZ seizure threshold in non-stressed and stressed mice: possible involvement of noradrenergic mechanism. Neuropeptides, 2006, Volume: 40, Issue:5 Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin III; Animals; Convulsants; Desipramine; Imidazoles; Injections, Intraperitoneal; Injections, Intraventricular; Losartan; Male; Mice; Mice, Inbred ICR; Norepinephrine; Pentylenetetrazole; Pyridines; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Restraint, Physical; Seizures; Stress, Psychological; Sympathetic Nervous System	2006